Universität zu Köln

Shanafelt, Tait D., Parikh, Sameer A., Noseworthy, Peter A., Goede, Valentin, Chaffee, Kari G., Bahlo, Jasmin, Call, Timothy G., Schwager, Susan M., Ding, Wei, Eichhorst, Barbara, Fischer, Kirsten, Leis, Jose F., Chanan-Khan, Asher Alban, Hallek, Michael, Slager, Susan L. and Kay, Neil E. (2017). Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk. Lymphoma, 58 (7). S. 1630 - 1640. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Full text not available from this repository.

Abstract

Although preliminary data suggests that ibrutinib may increase risk of atrial fibrillation (AF), the incidence of AF in a general cohort of chronic lymphocytic leukemia (CLL) patients is unknown. We evaluated the prevalence of AF at CLL diagnosis and incidence of AF during follow-up in 2444 patients with newly diagnosed CLL. A prior history of AF was present at CLL diagnosis in 148 (6.1%). Among the 2292 patients without history of AF, 139 (6.1%) developed incident AF during follow-up (incidence approximately 1%/ year). Older age (p <. 0001), male sex (p = .01), valvular heart disease (p = .001), and hypertension (p = .04) were associated with risk of incident AF on multivariate analysis. A predictive model for developing incident AF constructed from these factors stratified patients into 4 groups with 10-year rates of incident AF ranging from 4% to 33% (p <. 0001). This information provides context for interpreting rates of AF in CLL patients treated with novel therapies.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Shanafelt, Tait D. UNSPECIFIED UNSPECIFIED UNSPECIFIED Parikh, Sameer A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Noseworthy, Peter A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Goede, Valentin UNSPECIFIED UNSPECIFIED UNSPECIFIED Chaffee, Kari G. UNSPECIFIED UNSPECIFIED UNSPECIFIED Bahlo, Jasmin UNSPECIFIED UNSPECIFIED UNSPECIFIED Call, Timothy G. UNSPECIFIED UNSPECIFIED UNSPECIFIED Schwager, Susan M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ding, Wei UNSPECIFIED UNSPECIFIED UNSPECIFIED Eichhorst, Barbara UNSPECIFIED UNSPECIFIED UNSPECIFIED Fischer, Kirsten UNSPECIFIED UNSPECIFIED UNSPECIFIED Leis, Jose F. UNSPECIFIED UNSPECIFIED UNSPECIFIED Chanan-Khan, Asher Alban UNSPECIFIED UNSPECIFIED UNSPECIFIED Hallek, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Slager, Susan L. UNSPECIFIED UNSPECIFIED UNSPECIFIED Kay, Neil E. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-246545
DOI:	10.1080/10428194.2016.1257795
Journal or Publication Title:	Leuk. Lymphoma
Volume:	58
Number:	7
Page Range:	S. 1630 - 1640
Date:	2017
Publisher:	TAYLOR & FRANCIS LTD
Place of Publication:	ABINGDON
ISSN:	1029-2403
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language NATURAL-HISTORY; RISK-FACTORS; OPEN-LABEL; INITIAL THERAPY; LIFETIME RISK; IBRUTINIB; STROKE; COHORT; TRIAL; CYCLOPHOSPHAMIDE Multiple languages Oncology; Hematology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/24654